Chromatine/Épigénétique
Les inhibiteurs de la chromatine/épigénétique sont des composés qui modulent la structure et la fonction de la chromatine ou interfèrent avec les modifications épigénétiques, telles que la méthylation de l'ADN et la modification des histones. Ces inhibiteurs sont des outils essentiels pour étudier la régulation de l'expression génique et le rôle de l'épigénétique dans des maladies telles que le cancer, les troubles neurologiques et les anomalies du développement. En ciblant les processus épigénétiques, ces inhibiteurs peuvent modifier les schémas d'expression génique et offrir de nouvelles perspectives thérapeutiques. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de la chromatine/épigénétique de haute qualité pour soutenir vos recherches en biologie moléculaire, génétique et épigénétique.
Sous-catégories appartenant à la catégorie "Chromatine/Épigénétique"
2235 produits trouvés pour "Chromatine/Épigénétique"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Vafidemstat
CAS :<p>Vafidemstat (ORY-2001) is a lysine-histone demethylase (LSD1)/MAO-B inhibitor for the study of neurological disorders.</p>Formule :C19H20N4O2Degré de pureté :99.53%Couleur et forme :SolidMasse moléculaire :336.39CD235
CAS :<p>CD235 is a structurally similar analog of CD161. CD161 is an orally bioavailable inhibitor of BET bromodomain.</p>Formule :C26H20FN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :453.47GSK-3484862
CAS :<p>Gsk-3484862 is a non covalent inhibitor of DNA methyltransferase DNMT1 with anticancer activity.</p>Formule :C19H19N5OSDegré de pureté :99.87% - 99.963%Couleur et forme :SolidMasse moléculaire :365.45YM-08
CAS :<p>YM-08 (Compound 7a), a brain-penetrant SIRT2 inhibitor, exhibits an IC50 of 19.9 μM. Additionally, it acts as an inhibitor of Hsp70 [1].</p>Formule :C19H17N3OS2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :367.49MAK683-CH2CH2COOH
CAS :<p>MAK683-CH2CH2COOH, an EED-targeting chemical, serves as a foundation for EED degrader-1 and PROTAC EED degrader-2 design.</p>Formule :C23H21FN6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.45(1s,4s)-Menin-MLL inhibitor-23
<p>(1s,4s)-Menin-MLL Inhibitor-23, an enantiomer of Menin-MLL Inhibitor-23 (Example 99A), functions as an inhibitor of the menin-MLL interaction [1].</p>Formule :C36H53FN6O4Couleur et forme :SolidMasse moléculaire :652.84PHD2/HDACs-IN-1
CAS :<p>PHD2/HDACs-IN-1: strong PHD2/HDAC inhibitor (IC50: 1.15-26.60 μM), low-toxicity, protects kidneys from cisplatin-induced AKI.</p>Formule :C18H19N9O4Couleur et forme :SolidMasse moléculaire :425.4BRD-IN-3
CAS :<p>BRD-IN-3 is a highly potent PCAF bromodomain (BRD) inhibitor (IC50: 7 nM). It also exhibits activity against GCN5 and FALZ.</p>Formule :C21H25N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :395.45SMYD3-IN-1
CAS :<p>SMYD3-IN-1 is an irreversible and selective SMYD3 (SET and MYND domain containing 3) inhibitor(IC50 of 11.7 nM).</p>Formule :C28H31ClN4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :507.02TCS HDAC6 20b
CAS :<p>TCS HDAC6 20b (HDAC6-IN-7) is an HDAC6 inhibitor that blocks the growth of breast cancer cells and can be used in cancer research.</p>Formule :C26H44N2O4SDegré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :480.7KDM4-IN-2
CAS :<p>KDM4-IN-2 is a potent and selective KDM4/KDM5 dual inhibitor with Kis of 4 and 7 nM for KDM4A and KDM5B, respectively.</p>Formule :C25H26N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :426.51MK-0626
CAS :<p>MK-0626 is an orally available dipeptidyl peptidase IV (DPP-4) inhibitor enhancing AMP, restoring the expression of GLP-1R. promoting neoangiogenesis.</p>Formule :C22H24F2N6O2Degré de pureté :99.47% - >99.99%Couleur et forme :SolidMasse moléculaire :442.46Tankyrase-IN-5
CAS :<p>Tankyrase-IN-5 (Compound 30f), structurally related to MSC2504877, effectively inhibits tankyrase isoforms TNKS1 and TNKS2, with half-maximal inhibitory</p>Formule :C17H18N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :282.34PRMT5-IN-28
CAS :<p>PRMT5-IN-28 (compound 36) serves as an inhibitor of the protein arginine methyltransferase 5 (PRMT5) enzyme, which is implicated in various cellular processes</p>Formule :C18H19ClN4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :406.82Brepocitinib
CAS :<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Formule :C18H21F2N7ODegré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :389.4JAK-IN-5
CAS :<p>JAK-IN-5 is a JAK inhibitor.</p>Formule :C27H31FN6ODegré de pureté :98.1% - 99.37%Couleur et forme :SolidMasse moléculaire :474.57PHD-IN-2
CAS :<p>PHD-IN-2 (Compound 91), a potent PHD antagonist with an IC50 of less than 5 nM, effectively stimulates erythropoietin synthesis in HEP3B cells with an EC50 of</p>Formule :C26H27N7O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :501.54PRMT5-IN-29
CAS :<p>PRMT5-IN-29 is a potent, orally active inhibitor of PRMT5, exhibiting an IC50 value of 1.5 μM, showing promise for use in advanced cancer research [1].</p>Formule :C18H20Cl3N5O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :492.74PRMT5-IN-25
CAS :<p>PRMT5-IN-25 (compound 503) is a potent inhibitor of PRMT5, exhibiting an inhibition constant (K i) of 0.06 nM and demonstrating antiproliferative properties [1</p>Formule :C24H21F3N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :466.46PARP7-IN-15
CAS :<p>PARP7-IN-15 (Compound 18) is a potent PARP7 inhibitor exhibiting an IC50 of 0.56 nM and demonstrates antitumor activity [1].</p>Formule :C23H24F6N6O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :562.46KDM5-C70
CAS :<p>KDM5-C70 is an ethyl ester derivative of KDM5-C49.</p>Formule :C17H28N4O3Degré de pureté :97.63% - 99.86%Couleur et forme :SolidMasse moléculaire :336.43Pim-1 kinase inhibitor 5
CAS :<p>Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-</p>Formule :C22H13Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :406.26Sirtuin-1 inhibitor 1
CAS :<p>Sirtuin-1 inhibitor 1 is an inhibitor against deacetylase-1 (Sirtuin-1) and can be used to study senescence and cell death in the organism.</p>Formule :C20H17N3O2Degré de pureté :99.1%Couleur et forme :SolidMasse moléculaire :331.37BRD7-IN-1
CAS :<p>BRD7-IN-1, a BI7273 derivative, forms PROTAC VZ185, targeting BRD7/9 with DC50s of 4.5/1.8 nM via VHL ligand linkage.</p>Formule :C22H28Cl2N4O3Degré de pureté :98.95%Couleur et forme :SolidMasse moléculaire :467.39Aurora Kinases-IN-4
CAS :<p>Aurora Kinases-IN-4 (Compound 11c) is a covalent, ATP-competitive inhibitor of aurora kinase A with an IC50 value of 1.7 nM.</p>Formule :C26H28N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.55Physachenolide C
CAS :<p>Physachenolide C, a selective BET inhibitor, induces apoptosis and arrests the cell cycle at the G0-G1 phase, exhibiting antitumor activity [1].</p>Formule :C30H40O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :544.63PHD2-IN-1
CAS :<p>PHD2-IN-1, a potent and orally active HIF prolyl hydroxylase 2 (PHD2) inhibitor, exhibits an IC50 of 22.53 nM and is applicable in anemia research [1].</p>Formule :C21H23ClN4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :446.88BET-IN-16
CAS :<p>BET-IN-16 (Comp I), a bromodomain and extra-terminal (BET) inhibitor, demonstrates anticancer activity by impeding the growth of prostate cancer cells.</p>Formule :C31H25N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :515.56Antitumor agent-101
CAS :<p>Antitumor agent-101 is a selective, covalent inhibitor targeting lysine methyltransferases G9a/GLP, demonstrating IC50 values of 8.5 nM for G9a and 5.5 nM for</p>Formule :C26H38N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :482.62SJ1461
CAS :<p>SJ1461 is a potent, orally active inhibitor of the BET family, selectively targeting and inhibiting BRD2 (BD1), BRD2 (BD2), BRD4 (BD1), and BRD4 (BD2) with</p>Formule :C21H18ClN7OS2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :484CBP-IN-1
CAS :<p>CBP-IN-1 (compound 12) acts as a potent CBP inhibitor exhibiting an IC50 of 1.5 nM and additionally suppresses CBP BRET and BRD4(1) with IC50 values of 690 nM</p>Formule :C27H33F2N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :509.59Eleven-Nineteen-Leukemia Protein IN-2
CAS :<p>Eleven-Nineteen-Leukemia Protein IN-2 (compound 23), an ENL inhibitor, exhibits an IC50 of 10.7 nM and is utilized for leukemia research [1].</p>Formule :C22H23N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :389.45LSD1-UM-109
CAS :<p>LSD1-UM-109 is a highly potent and reversible inhibitor of LSD1, demonstrating an IC50 of 3.1 nM.</p>Formule :C29H27FN6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :478.56Bromodomain inhibitor-12
CAS :<p>Bromodomain Inhibitor-12 (example 303) is a research compound utilized in the study of autoimmune and inflammatory diseases [1].</p>Formule :C28H38N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :510.63MAT2A-IN-10
CAS :<p>MAT2A-IN-10 (Compound 28), an orally active inhibitor of MAT2A, exhibits an IC50 of 26 nM and is utilized in cancer research [1].</p>Formule :C27H24F2N6O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :534.51PIM1-IN-4
CAS :<p>PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.</p>Formule :C27H25BrCl2CuN6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :663.88Eleven-Nineteen-Leukemia Protein IN-3
CAS :<p>ENL YEATS inhibitor Eleven-Nineteen-Leukemia Protein IN-3, IC50 15.4 nM, orally active, suppresses MYC, stabilizes ENL in vitro.</p>Formule :C28H27N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.55MAT2A-IN-12
CAS :<p>MAT2A Allosteric Inhibitor 2 is a potent, selective inhibitor exhibiting an IC50 of 5 nM and demonstrates nanomolar efficacy (IC50 = 5 μM) in proliferation</p>Formule :C20H17NO3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :319.35CBP/p300-IN-21
CAS :<p>CBP/p300-IN-21 (Compound 5d), a selective inhibitor of CBP/p300 with IC50 values of 0.07 μM for p300 and 1.755 μM for CBP, reduces H3K18Ac levels and inhibits</p>Formule :C19H16ClNO4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :357.79BRD4 Inhibitor-28
CAS :<p>BRD4 Inhibitor-28 (Compound 18), an orally active molecule, selectively inhibits the bromodomains of BRD4 (BRD4-BD1 and BRD4-BD2) with IC50 values of 15 and 55</p>Formule :C23H21N3O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :387.43Bromodomain inhibitor-12 (edisylate)
CAS :<p>Bromodomain Inhibitor-12 Edisylate (example 303) serves as a bromodomain inhibitor applicable to autoimmune and inflammatory disease research [1].</p>Formule :C30H44N4O11S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :700.82HIF-2α-IN-9
CAS :<p>HIF-2α-IN-9 (compound 35r) serves as an HIF-2α inhibitor, effectively suppressing VEGF-A with an IC50 of 305 nM, and modulating growth-promoting genes within</p>Formule :C12H13F5O4S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.35(S,R)-CFT8634
CAS :<p>(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular</p>Formule :C37H45F3N6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :710.79FM-479
CAS :<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formule :C25H26N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :442.523WM-586
CAS :<p>WM-586 is a covalent inhibitor of WDR5 that impedes the WDR5-MYC binding.</p>Formule :C20H20F3N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :467.47JG-2016
CAS :<p>JG-2016, as a histone acetyltransferase 1 inhibitor, inhibits growth of human cancer cell lines and inhibits enzymatic activity in cellulose.</p>Formule :C18H21ClN4O3Degré de pureté :99.00% - 99.37%Couleur et forme :SolidMasse moléculaire :376.84GSK217
CAS :<p>GSK217 is a potent and selective inhibitor of the bromo and extraterminal domain (BET) second bromodomain (BD2) with high solubility, utilized in oncology and</p>Formule :C20H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :360.41AGI-25696
CAS :<p>AGI-25696 inhibits MATA2, blocking MTAP-deleted tumor growth, potential for cancer research.</p>Formule :C27H18N4ODegré de pureté :98.40% - 99.74%Couleur et forme :SolidMasse moléculaire :414.46JAK-IN-31
CAS :<p>JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,</p>Formule :C21H19N7O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.55ABBV-712
CAS :<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Formule :C24H28N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :452.5GSK737
CAS :<p>GSK737 is a dual inhibitor of BRD4 BD1 and BD2, exhibiting pIC50 values of 5.3 and 7.3, respectively.</p>Formule :C20H21N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :363.41AAPK-25
CAS :<p>AAPK-25, a dual Aurora/PLK inhibitor, disrupts mitosis, induces apoptosis, and has antitumor properties.</p>Formule :C21H13Cl2N3O2SDegré de pureté :97.05%Couleur et forme :SolidMasse moléculaire :442.32Demethyleneberberine chloride
CAS :<p>Demethyleneberberine chloride, a natural mitochondria-targeted antioxidant, mitigates colitis in mice and suppresses inflammatory responses by blocking the NF-</p>Formule :C19H18ClNO4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :359.8Amelparib
CAS :<p>Amelparib (JPI-289) is an inhibitor of the poly-ADP-ribose polymerase.</p>Formule :C19H25N3O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :343.42BATCP
CAS :<p>BATCP is an inhibitor of histone deacetylases (HDAC) [1].</p>Formule :C23H28F3N3O6Couleur et forme :SolidMasse moléculaire :499.487AKB-6899
CAS :<p>AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated</p>Formule :C14H11FN2O4Degré de pureté :97.87%Couleur et forme :SolidMasse moléculaire :290.25Sirt2-IN-5
CAS :<p>Sirt2-IN-5 is a potent inhibitor of SIRT2.</p>Formule :C26H27Cl2N5O3Couleur et forme :SolidMasse moléculaire :528.43MARK-IN-1
CAS :<p>MARK-IN-1 is a potent microtubule affinity regulating kinase (MARK) inhibitor, (IC50<0.25 nM).</p>Formule :C22H23F2N7OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :471.53XDM-CBP
CAS :<p>XDM-CBP is an effective and selective CBP/p300 bromodomain inhibitor.</p>Formule :C21H22N2O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :366.41DY-46-2
CAS :<p>DY-46-2 is a DNMT3A inhibitor (IC50: 0.39 ± 0.23 μM) with anticancer activity and is used in cancer and tumor research.</p>Formule :C19H22N6O5SDegré de pureté :99.12% - 99.12%Couleur et forme :SolidMasse moléculaire :446.48Prolyl Hydroxylase inhibitor 1
CAS :<p>Prolyl Hydroxylase inhibitor 1 is an orally active inhibitor of hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) (IC50 of 62.23 nM).</p>Formule :C19H18ClN5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :415.83K-756
CAS :<p>K-756 is a direct and selective inhibitor of tankyrase (TNKS), which inhibits the ADP-ribosylation activity of TNKS1 (IC50 = 31 nM) and TNKS2 (IC50 = 36 nM).</p>Formule :C24H27N5O3Degré de pureté :99.81%Couleur et forme :SolidMasse moléculaire :433.5QL-1200186
CAS :<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Formule :C26H27N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :485.54JAK kinase-IN-1
CAS :<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Formule :C17H19F2N7OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.44JAK-IN-25
CAS :<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formule :C19H17N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :379.37JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formule :C33H38F2N6O8Couleur et forme :SolidMasse moléculaire :684.69GSK-A
CAS :<p>GSK-A is a Histone Lysine Methyltransferase EZH2 inhibitor.</p>Formule :C21H25N5O2Couleur et forme :SolidMasse moléculaire :379.46BChE/HDAC6-IN-1
CAS :<p>BChE/HDAC6-IN-1 is a dual BChE/HDAC6 inhibitor that exhibits potent and selective inhibition with IC50 values of 4 nM for BChE and 8.9 nM for HDAC6.</p>Formule :C34H43N5O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :601.74KDM2B-IN-1
CAS :<p>KDM2B-IN-1: Potent, specific KDM2B histone demethylase inhibitor for hyperproliferative disease research.</p>Formule :C21H30N4O2SCouleur et forme :SolidMasse moléculaire :402.56HDAC/HSP90-IN-3
CAS :<p>HDAC/HSP90-IN-3, a dual inhibitor targeting fungal Hsp90 (IC50: 0.83 μM) & HDAC (IC50: 0.91 μM), counters azole-resistant C. albicans.</p>Formule :C26H33N5O6Couleur et forme :SolidMasse moléculaire :511.57RK-701
CAS :<p>RK-701: G9a inhibitor, IC50 23-27 nM, increases HbF/γ-Globin/BGLT3, decreases H3K9me2, inhibits BCL11A/ZBTB7A.</p>Formule :C26H30N4O3Couleur et forme :SolidMasse moléculaire :446.54Aurora kinase inhibitor-8
CAS :<p>Aurora kinase inhibitor-8 is a highly selective inhibitor of Aurora kinase.</p>Formule :C30H29N7O3Couleur et forme :SolidMasse moléculaire :535.6EPZ-030456
CAS :<p>EPZ-030456 is an effective and selective inhibitor of the SMYD3.</p>Formule :C28H34ClN5O4SCouleur et forme :SolidMasse moléculaire :572.12PF-06679142
CAS :<p>PF-06679142 is an effective AMPK activator. PF-06679142 exhibited robust activation of AMPK in rat kidneys as well as desirable oral absorption.</p>Formule :C20H17F2NO3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :357.35CC-90005
CAS :<p>CC-90005 is a potent, selective oral PKC-θ inhibitor with an IC50 of 8 nM, preferential over PKC-δ, and inhibits T cell activation.</p>Formule :C21H27F2N7O2Couleur et forme :SolidMasse moléculaire :447.48PRMT5-IN-16
CAS :<p>PRMT5-IN-16 (Compound 20) is an antitumor PRMT5 inhibitor linked to epigenetic changes.</p>Formule :C25H34N8O2Couleur et forme :SolidMasse moléculaire :478.59Tyk2-IN-9
CAS :<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formule :C20H17N9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :383.41OM-1700
CAS :<p>OM-1700 inhibits tankyrase 1 (IC50=127 nM) and 2 (IC50=14 nM); hinders colon cancer cell growth, COLO 320DM (GI50=650 nM).</p>Formule :C25H23FN6O2Couleur et forme :SolidMasse moléculaire :458.49FD1024
CAS :<p>FD1024 is a potent PIM inhibitor, displaying inhibitory concentrations (IC50s) of 1.96 nM, 38.9 nM, and 4.17 nM for PIM1, PIM2, and PIM3, respectively.</p>Formule :C21H20F2N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :430.47NMS-P515
CAS :<p>NMS-P515 is an effective, orally active, and stereospecific PARP-1 inhibitor (Kd: 16 nM and an IC50: 27 nM (in Hela cells)). It has anti-tumor activity.</p>Formule :C21H29N3O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :355.47CARM1-IN-3
CAS :<p>CARM1-IN-3 (compound 17b) is a potent, selective inhibitor of co-activator associated arginine methyltransferase (CARM1), exhibiting IC50 values of 0.07 µM for</p>Formule :C24H32N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :408.54RK-0133114
<p>RK-0133114, R-enantiomer of RK-701, is a G9a inhibitor (IC50 = 3.7 μM) for SCD research.</p>Formule :C26H30N4O3Couleur et forme :SolidMasse moléculaire :446.54JQKD82 dihydrochloride
CAS :<p>JQKD82 (JADA82) dihydrochloride, a cell-permeable and selective inhibitor of KDM5, enhances H3K4me3 levels, making it effective for multiple myeloma research [1].</p>Formule :C27H42Cl2N4O5Couleur et forme :SolidMasse moléculaire :573.55QQN-00358
CAS :<p>QQN-00358 is a novel potent and selective tankyrase (TNKS) inhibitor.</p>Formule :C26H24F3N3O4Couleur et forme :SolidMasse moléculaire :499.48PARP1-IN-7
CAS :<p>PARP1-IN-7 functions as an anticancer agent by inhibiting poly(ADP-ribose) polymerase-1 (PARP1).</p>Formule :C24H23N5OCouleur et forme :SolidMasse moléculaire :397.47MS31
CAS :<p>MS31 is a potent and highly affinity inhibitor of spindlin 1 (SPIN1).</p>Formule :C20H27N3O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :341.45Upadacitinib tartrate
CAS :<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formule :C21H33F3N6O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :602.521CBP/p300-IN-15
CAS :<p>CBP/p300-IN-15 inhibits p300 (IC50: 2.5 nM) & CBP (28 nM), affects OVCAR-3 (EC50: 0.865 μM) & A2780 cells (2.71 μM) for ovarian cancer research.</p>Formule :C26H28N4O5Couleur et forme :SolidMasse moléculaire :476.52Ro 32-0432 hydrochloride
CAS :<p>Ro 32-0432 is a selective, ATP-competitive, oral pan-PKC inhibitor exhibiting inhibitory effects on PKCα, PKCβI, PKCβII, PKCγ, and PKCε.</p>Formule :C28H28N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :452.55BET-IN-9
CAS :<p>BET-IN-9 is a BET inhibitor[1].</p>Formule :C22H24N4O3Couleur et forme :SolidMasse moléculaire :392.45PIM-IN-2
CAS :<p>PIM-IN-2 (Pim-2) is a potent inhibitor of Pim kinases, demonstrating an inhibition concentration half-maximal (IC50) value of 25 nM .</p>Formule :C19H22N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :338.4SP-2-225
CAS :<p>SP-2-225, a selective inhibitor of HDAC6, augments the production of cancer-associated antigens and enhances macrophage antigen cross-presentation to T cells,</p>Formule :C28H34N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :446.58MARK-IN-2
CAS :<p>MARK-IN-2 is a potent microtubule affinity regulating kinase (MARK) inhibitor,(IC50:5 nM).</p>Formule :C18H18ClF2N5OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :425.88PIN1 inhibitor 2
CAS :<p>PIN1 inhibitor 2, compound 12, impedes PIN1, shows promise in breast cancer study, and has IC50 of 9.55 μM in MCF7 cells.</p>Formule :C16H21N3S2Couleur et forme :SolidMasse moléculaire :319.49CBB1007
CAS :<p>CBB1007 is a potent, reversible, and substrate competitive LSD1 inhibitor (IC50: 5.27 μM for hLSD1).</p>Formule :C27H34N8O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :534.61AMPK activator 7
CAS :<p>AMPK activator 7 (I-3-24, EC50: 8.8 nM) targets AMPK-related disorders like type 2 diabetes and obesity.</p>Formule :C23H22F3N3O5Couleur et forme :SolidMasse moléculaire :477.43PARP7-probe-1
CAS :<p>PARP7-probe-1: biotinylated, chemiluminescent PARP7 active site probe for research use.</p>Formule :C36H49F3N8O5SCouleur et forme :SolidMasse moléculaire :762.89PRT543
CAS :<p>PRT543 is a potent selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), showing a wide range of antitumor activities in vitro and in vivo. The compound also showed an inhibitory effect on methyltransferase activity of the PRMT5/MEP50 complex with an IC50 value of 10.8 nM.</p>Formule :C17H17ClN4O4Couleur et forme :SolidMasse moléculaire :376.79JAK-IN-24
CAS :<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formule :C20H25N5O2Couleur et forme :SolidMasse moléculaire :367.44EZH2-IN-14
CAS :<p>EZH2-IN-14 selectively inhibits EZH2 at 12 nM IC50, has >200-fold specificity over EZH1, reducing H3K27me3 levels.</p>Formule :C31H39N7O2Couleur et forme :SolidMasse moléculaire :541.69TC-A 2317 hydrochloride
CAS :<p>TC-A 2317 HCl inhibits Aurora A kinase (Ki 1.2 nM) over Aurora B (Ki 101 nM), displaying antitumor effects.</p>Formule :C19H29ClN6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :392.93TC-AC28
CAS :<p>TC-AC28 is a novel potent and selective Brd2(2) ligand.</p>Formule :C23H21N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :415.44Nesuparib
CAS :<p>Nesuparib, a potent PARP/TNKS1 inhibitor, has antitumor properties and potential for treating various diseases.</p>Formule :C23H24N6ODegré de pureté :99.71%Couleur et forme :SolidMasse moléculaire :400.48GSK4028
CAS :<p>GSK4028 is the enantiomeric negative control of GSK4027, a PCAF/GCN5 bromodomain chemical probe, with a pIC50 of 4.9 in a TR-FRET assay.</p>Formule :C17H21BrN4OCouleur et forme :SolidMasse moléculaire :377.28HL23
CAS :<p>HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC).</p>Formule :C44H44N2O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :712.83BRD4 Inhibitor-23
CAS :<p>BRD4 Inhibitor-23: potent, oral, IC50: BRD4 BD-1 6.21 nM, BD-2 1.44 nM. See WO2022033542A1 Example 1.</p>Formule :C22H19F2N3O4SCouleur et forme :SolidMasse moléculaire :459.47HIF-2α-IN-6
CAS :<p>HIF-2α-IN-6 (117) is a HIF-2α inhibitor [1].</p>Formule :C15H13F4NO3SCouleur et forme :SolidMasse moléculaire :363.33TCS 21311
CAS :<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formule :C27H25F3N4O4Degré de pureté :99.39% - ≥98%Couleur et forme :SolidMasse moléculaire :526.51AMPK-IN-1
CAS :<p>AMPK-IN-1 is an activator of the AMP-activated protein kinase (AMPK) enzyme, specifically targeting the α2β2γ1 isoform with an EC50 of 551 nM.</p>Formule :C24H18ClN3O3Couleur et forme :SolidMasse moléculaire :431.87EPZ011989 HCl(1598383-40-4 Free base)
CAS :<p>EPZ011989 is a highly potent and selective oral EZH2 inhibitor with Ki value <3 nM.</p>Formule :C35H51N5O4·HClCouleur et forme :SolidMasse moléculaire :642.27TCJL37
CAS :<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formule :C17H11ClF2N4O2Couleur et forme :SolidMasse moléculaire :376.74CBP/p300-IN-19
CAS :<p>CBP/p300-IN-19 inhibits p300/CBP HAT (IC50: 1.4μM), less effective on PCAF/Myst3, shows anti-tumor properties.</p>Formule :C30H27N3O3Couleur et forme :SolidMasse moléculaire :477.55GSK2646264
CAS :<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Formule :C24H26N2O2Couleur et forme :SolidMasse moléculaire :374.48Gö 7874
CAS :<p>Gö 7874 is a potent, reversible, ATP-competitive, and selective inhibitor of protein kinase C (IC50 = 4 nM for rat brain PKC).</p>Formule :C27H26N4O4Couleur et forme :SolidMasse moléculaire :470.52HSP70/SIRT2-IN-2
CAS :<p>HSP70/SIRT2-IN-2 (Compounds 1a), a dual inhibitor of SIRT2 and HSP70, exhibits an IC50 of 45.1±5.0 μM against SIRT2 and demonstrates antitumor activity [1].</p>Formule :C17H13N3S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :355.5LY3295668
CAS :<p>LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively.</p>Formule :C24H26ClF2N5O2Degré de pureté :99.68%Couleur et forme :SolidMasse moléculaire :489.95GNE-375
CAS :<p>GNE-375 is a selective and potent BRD9 inhibitor (IC50: 5 nM).GNE-375 inhibits BRD4, TAF1, and CECR2, and can be used to study epigenetic resistance.</p>Formule :C25H29N3O5Degré de pureté :98.99%Couleur et forme :SolidMasse moléculaire :451.51HIF-2α agonist 2
CAS :<p>HIF-2α agonist 2 is an HIF-2α agonist with an EC50 value of 1.68 μM for HIF-2α.</p>Formule :C13H8Br2N2O2SDegré de pureté :98.87%Couleur et forme :SoildMasse moléculaire :416.09EPZ031686
CAS :<p>EPZ031686 is an effective inhibitor of SMYD3 inhibitor with an IC50 of 3 nM and can be used in studies about cancer.</p>Formule :C26H34ClF3N4O4SDegré de pureté :99.67%Couleur et forme :SolidMasse moléculaire :591.09E7016
CAS :<p>E7016 (GPI 21016) is an orally available PARP inhibitor. E7016 inhibits of DNA repair. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo.</p>Formule :C20H19N3O3Degré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :349.38CPI-0610 carboxylic acid
CAS :<p>CPI-0610 carboxylic acid is a selective BET protein inhibitor with potential anticancer effects.</p>Formule :C20H15ClN2O3Degré de pureté :98.62%Couleur et forme :SolidMasse moléculaire :366.8JAK-IN-3
CAS :<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Formule :C18H20N4O3Degré de pureté :98.04% - 98.19%Couleur et forme :SolidMasse moléculaire :340.38NPAS3-IN-1
CAS :<p>NPAS3-IN-1 is an NPAS3-ARNT heterodimerization inhibitor that regulates NPAS3 transcription by modulating the heterodimerization of NPAS3 with ARNT.</p>Formule :C10H5N3O2S3Degré de pureté :99.56%Couleur et forme :SolidMasse moléculaire :295.36hRIO2 kinase ligand-1
CAS :<p>hRIO2 kinase ligand-1 is a potent ligand for hRIO2 kinase (Kd: 520 nM).</p>Formule :C17H14N2ODegré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :262.31CCT129202
CAS :<p>CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively.</p>Formule :C23H25ClN8OSDegré de pureté :98.14%Couleur et forme :SolidMasse moléculaire :497.02KDM4-IN-4
CAS :<p>KDM4-IN-4 is a KDM4 inhibitor with anticancer activity that inhibits the KDM4A-Tudor structural domain for cancer research.</p>Formule :C16H23NODegré de pureté :99.61%Couleur et forme :SolidMasse moléculaire :245.36AU-15330
CAS :<p>AU-15330 is a proteolytic targeting chimera (PROTAC) that simultaneously targets SMARCA4, SMARCA2, and PBRM1 for degradation and exhibits cytotoxicity in H3.3K27M cells but not in H3 wild-type cells. Cost-effective and quality-assured.</p>Formule :C39H49N9O5SDegré de pureté :98.21% - 99.62%Couleur et forme :SolidMasse moléculaire :755.93PARP-1-IN-4
CAS :<p>PARP-1-IN-4 is a potent PARP-1 inhibitor with potential see anti-tumor activity, and inhibition of PARP-1 may be used in cancer development.</p>Formule :C22H15Cl2N3O2Degré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :424.28FHT-1015
CAS :<p>FHT-1205 is a potent inhibitor (IC50 ≤ 10 nM) of SMARCA4/SMARCA2 ATPase (BRG1 and BRM).</p>Formule :C25H25N5O4S3Degré de pureté :98.57%Couleur et forme :SolidMasse moléculaire :555.69HS94
CAS :<p>HS94 (DAPK3 inhibitor HS94) is a selective and potent DAPK3 inhibitor with a Ki value of 126 nM for Pim kinase inhibition and can be used to study hypertension.</p>Formule :C15H15N5O2SDegré de pureté :95.04%Couleur et forme :SolidMasse moléculaire :329.38Y06137
CAS :<p>Y06137, selective BET inhibitor, Kd 81 nM for BRD4(1), researched for castration-resistant prostate cancer treatment.</p>Formule :C27H32N4O2Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :444.57CeMMEC1
CAS :<p>CeMMEC1 is an inhibitor of BRD4, and also has a great affinity for TAF1(IC50=0.9 μM).</p>Formule :C19H16N2O4Degré de pureté :98.9% - 99.92%Couleur et forme :SolidMasse moléculaire :336.34Aurora B inhibitor 1
CAS :<p>Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor (Ki <0.010 uM) with potential anticancer activity for cancer research.</p>Formule :C25H26ClF2N7O2Degré de pureté :98.37%Couleur et forme :SolidMasse moléculaire :529.97L-Moses dihydrochloride
<p>L-Moses (L-45) dihydrochloride is the first, potent, selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor (Kd: 126 nM).</p>Formule :C21H26Cl2N6Couleur et forme :SolidMasse moléculaire :433.38MC2652
<p>MC2652, a potent LSD1 inhibitor, suppresses leukemia (MV4-11, NB4) and impedes prostate cancer (LNCaP) cell growth.</p>Formule :C22H20N2OCouleur et forme :SolidMasse moléculaire :328.41KDOAM-25 citrate
CAS :<p>KDOAM-25 citrate inhibits KDM5A/B/C/D (IC50: 71, 19, 69, 69 nM); boosts H3K4 methylation, hinders MM1S cell growth. [1]</p>Formule :C21H33N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :499.51BSI-401
CAS :<p>BSI-401 is an oral inhibitor of PARP-1. It can inhibit pancreatic cancer either when used alone or in synergy with Oxaliplatin.</p>Formule :C9H4INO4Couleur et forme :SolidMasse moléculaire :317.037HDAC6-IN-13
<p>HDAC6-IN-13: potent, selective HDAC6 inhibitor; oral; IC50=0.019μM; targets HDAC1/2/3; crosses blood-brain barrier; anti-inflammatory.</p>Formule :C23H22N4OCouleur et forme :SolidMasse moléculaire :370.45DS-9300
CAS :<p>DS-9300, an orally administered potent and selective inhibitor of EP300/CBP HAT, exhibits a significant inhibitory activity with an IC50 value of 28 nM.</p>Formule :C25H26F3N5O3Couleur et forme :SolidMasse moléculaire :501.506K465
CAS :<p>6K465 is a potent Aurora A kinase inhibitor that reduces c-MYC and N-MYC oncoproteins, showing antiproliferative effects in SCLC and breast cancer cell lines.</p>Formule :C26H33ClFN9ODegré de pureté :99.78%Couleur et forme :SolidMasse moléculaire :542.05Balomenib
CAS :<p>Balomenib is an inhibitor of the menin-MLL interaction, effectively blocking the men1-MLL4-43 interaction with an IC50 of less than 0.075 μM. It inhibits cell growth in MV4-11 (CC50 < 0.1 μM), MOLM-13 (CC50 0.1~0.5 μM), and HEK293 (CC50 < 2 μM) cells. Balomenib also exhibits antitumor activity.</p>Formule :C33H34F3N7O2Couleur et forme :SolidMasse moléculaire :617.664O6BTG-C8-αGlu
CAS :<p>O6BTG-C8-αGlu is an O6-methylguanine-DNA methyltransferase (MGMT) inhibitor with an IC50 of 0.45 μM. At a concentration of 0.1 μM, it fully inhibits MGMT in HeLaS3 cells and demonstrates no cytotoxicity even at prolonged high doses (up to 20 μM). This compound is suitable for research on MGMT-related cancers.</p>Formule :C24H34BrN5O7SCouleur et forme :SolidMasse moléculaire :616.525KH-259
<p>KH-259: potent, selective CNS-penetrant HDAC6 inhibitor with 0.26 μM IC50; shows antidepressant effects in mice.</p>Formule :C20H25N3O2Couleur et forme :SolidMasse moléculaire :339.43BRD4-IN-7
CAS :<p>BRD4-IN-7, also known as compound 120, acts as a BRD4 inhibitor.</p>Formule :C29H24F2N4O3Couleur et forme :SolidMasse moléculaire :514.52PAD2-IN-1 hydrochloride
<p>PAD2-IN-1 hydrochloride: potent, selective PAD2 inhibitor; 95x less on PAD4, 79x less on PAD3; benzimidazole derivative.</p>Formule :C25H30ClFN6O3Couleur et forme :SolidMasse moléculaire :517PRMT5-IN-50
CAS :<p>PRMT5-IN-50 is an orally active selective inhibitor of PRMT5, demonstrating good metabolic stability and low clearance in human liver microsomes. It inhibits SDMA/HCT116-MTAPdel and SDMA/HCT116-MTAPwt with IC50 values for symmetric arginine methylation inhibition at 1.0 and 536 nM, respectively, and antiproliferative IC50 values at 19 and 1620 nM, respectively. Additionally, PRMT5-IN-50 suppresses tumor growth in mice.</p>Formule :C26H23F3N6OCouleur et forme :SolidMasse moléculaire :492.496WIZ degrader 8
CAS :<p>WIZ degrader 8 (compound 10) is a potent and selective molecular glue degrader of the transcription factor WIZ, effectively inducing HbF expression. It promotes WIZ degradation and HbF induction, suggesting its potential use as an inhibitor for sickle cell disease.</p>Formule :C21H27N3O4Couleur et forme :SolidMasse moléculaire :385.457BRD4 Inhibitor-33
CAS :<p>BRD4 Inhibitor-33 (example 13), a potent inhibitor of BRD4, is applicable in research related to both acute and chronic kidney diseases [1].</p>Formule :C24H20N4O2Couleur et forme :SolidMasse moléculaire :396.44MAT2A-IN-19
CAS :<p>MAT2A-IN-19 (Compound I-3) is an inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 32.93 nM.</p>Formule :C23H15F5N6O3Couleur et forme :SolidMasse moléculaire :518.396JPHM-2-167
CAS :<p>PHM-2-167 (Compound 11) is a selective inhibitor of the prolyl hydroxylase domain enzyme (PHD). It inhibits PHD2 and PHD3 with IC50 values of 0.253 μM and 3.95 μM, respectively. PHM-2-167 is applicable for research in chronic kidney disease.</p>Formule :C30H28N6O2Couleur et forme :SolidMasse moléculaire :504.582MAT2A-IN-16
CAS :<p>MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP-/-HCT-116 cells, with an IC50 value of 20 nM.</p>Formule :C23H17ClN6OCouleur et forme :SolidMasse moléculaire :428.874LSD1/2-IN-4
<p>LSD1/2-IN-4, a PCPA derivative, inhibits LSD1 (Ki 0.11 μM) & LSD2 (Ki 130 μM), potentially useful in T-cell leukemia research.</p>Formule :C9H8BrF2NCouleur et forme :SolidMasse moléculaire :248.07PRMT5-IN-49
CAS :<p>PRMT5-IN-49 (Compound 4b16) is an inhibitor of PRMT5.</p>Formule :C19H22N2O2Couleur et forme :SolidMasse moléculaire :310.39MAT2A-IN-18
CAS :<p>MAT2A-IN-18 (Compound 15) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 50 nM or less.</p>Formule :C17H13ClN4OCouleur et forme :SolidMasse moléculaire :324.764JAK1-IN-9
CAS :<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formule :C16H13IN6Couleur et forme :SolidMasse moléculaire :416.22NSD2-PWWP1-IN-1
CAS :<p>NSD2-PWWP1-IN-1 (compound 31) is a potent inhibitor of NSD2-PWWP1 with an IC50 value of 0.64 µM, demonstrating potential applications in cancer research.</p>Formule :C28H30N4Couleur et forme :SolidMasse moléculaire :422.565NSD2-PWWP1-IN-2
CAS :<p>NSD2-PWWP1-IN-2 (compound 33) is a potent NSD2-PWWP1 inhibitor, exhibiting an IC50 value of 1.49 µM, indicating its potential utility in cancer research.</p>Formule :C29H30N4Couleur et forme :SolidMasse moléculaire :434.575MAT2A-IN-21
CAS :<p>MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.</p>Formule :C26H20F2N4O2Couleur et forme :SolidMasse moléculaire :458.459MAT2A-IN-20
CAS :<p>MAT2A-IN-20 (Compound A49) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of ≤50 nM. It also inhibits human UGT1A1 with an IC50 of 28.45 μM. Additionally, MAT2A-IN-20 exhibits antitumor activity in mouse models.</p>Formule :C26H24F2N6O4Couleur et forme :SolidMasse moléculaire :522.503HDAC-IN-27
<p>HDAC-IN-27 is a potent and orally active inhibitor of HDAC Class I (0.43 nM - 3.01 nM for HDAC1-3).</p>Formule :C20H22N4O2Couleur et forme :SolidMasse moléculaire :350.41(rac)-Talazoparib
CAS :<p>(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is an orally active inhibitor of PARP1/2, with Ki values of 1.2 nM and 0.87 nM, respectively. It inhibits cellular PARylation at an EC50 of 2.51 nM. This compound leads to the accumulation of DNA damage and suppresses the proliferation of BRCA1/2-mutated MX-1 and Capan-1 cells, with IC50 values of 0.3 nM and 5 nM, respectively. Additionally, (rac)-Talazoparib exhibits antitumor activity in mouse models.</p>Formule :C19H14F2N6OCouleur et forme :SolidMasse moléculaire :380.3515-AIQ hydrochloride
CAS :<p>5-AIQ hydrochloride is a water-soluble PARP-1 inhibitor and serves as a vital functional group in various medications. It mitigates tissue damage associated with hepatic ischemia-reperfusion, making it valuable for research into conditions related to liver ischemia-reperfusion.</p>Formule :C9H9ClN2OCouleur et forme :SolidMasse moléculaire :196.634NVS-BPTF-1
CAS :<p>NVS-BPTF-1 is a specific inhibitor of bromodomain and PHD finger containing transcription factor (BPTF), exhibiting a dissociation constant (K_D) of 71 nM [1].</p>Formule :C26H28FN7O3SCouleur et forme :SolidMasse moléculaire :537.61SRI-43265
CAS :<p>SRI-43265 (compound 40) inhibits the dimerization of human antigen R protein (HuR), which is involved in cancer and inflammation pathogenesis [1].</p>Formule :C19H20N6OCouleur et forme :SolidMasse moléculaire :348.4MAT2A-IN-17
CAS :<p>MAT2A-IN-17 is a potent inhibitor of MAT2A, with an IC50 of less than 100 nM. MAT2A-IN-17 is applicable in cancer research.</p>Formule :C23H18F3N7OCouleur et forme :SolidMasse moléculaire :465.431HDAC1-IN-3
<p>HDAC1-IN-3 is a potent inhibitor of Pf HDAC1.</p>Formule :C22H24ClN7O2Couleur et forme :SolidMasse moléculaire :453.92BET/Aurora kinase-IN-1
CAS :<p>BET/Aurora kinase-IN-1 (Compound 38) is a dual inhibitor of BET and Aurora kinases. It exhibits antiproliferative activity against various tumor cell lines and demonstrates significant antitumor efficacy in xenograft models of renal cell carcinoma and colon cancer, with tumor growth inhibition (TGI) rates of 45.99% and 53.06%, respectively.</p>Formule :C25H30FN7OCouleur et forme :SolidMasse moléculaire :463.55HDAC-IN-87
CAS :<p>HDAC-IN-87 (Compound XII6) is a non-selective HDAC inhibitor with pIC50 values of 6.9 for HDAC4 and 5.8 for HDAC6. It exhibits fungicidal activity against P. sorghi and P. pachyrhizi. The acute oral LD50 in both male and female rats is greater than 500 mg/kg.</p>Formule :C13H7F5N4O2SCouleur et forme :SolidMasse moléculaire :378.277HYDAMTIQ
CAS :<p>HYDAMTIQ, a PARP-1/2 inhibitor (IC 50 : 29-38 nM), exhibits a range of pharmacological effects including anticancer, anti-inflammatory, and ischemic protective properties. It effectively reduces pulmonary PARP activity and alleviates symptoms such as allergen-induced cough and dyspnea while also diminishing bronchial hyperresponsiveness to methacholine. Moreover, HYDAMTIQ shows potent tumor suppressor activity in various cancers such as ovarian, breast, prostate, pancreatic, and glioblastoma multiforme. Demonstrating in vivo efficacy, HYDAMTIQ has been tested in animal models for conditions like cerebral ischemia, asthma, and cancer [1].</p>Formule :C14H14N2O2SCouleur et forme :SolidMasse moléculaire :274.34BRD4 D1-IN-1
<p>BRD4 D1-IN-1 selectively inhibits BRD4 D1 (IC50 <0.092 μM, Kd 18 nM) with >500-fold specificity versus D2.</p>Formule :C32H37F3N6OCouleur et forme :SolidMasse moléculaire :578.67PHD2-IN-4
CAS :<p>PHD2-IN-4 (compound 1) is an inhibitor of PHD2, with an IC50 of 4 nM. It is utilized in research related to chronic kidney disease.</p>Formule :C21H19N5O3Couleur et forme :SolidMasse moléculaire :389.407SARS-CoV-2 nsp14-IN-1
<p>SARS-CoV-2 nsp14-IN-1 inhibits Nsp14 Mtase with an IC50 of 0.061 μM, affecting multiple substrates.</p>Formule :C20H20N6O5SCouleur et forme :SolidMasse moléculaire :456.48SIRT-IN-6
CAS :<p>SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with an IC50 value of >50 μM. It shows potential as a research agent for studies involving metabolic disorders, inflammation, cancer, and neurodegenerative diseases.</p>Formule :C7H4ClN3OSCouleur et forme :SolidMasse moléculaire :213.644Milpecitinib
CAS :<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463HDAC11-IN-2
CAS :<p>HDAC11-IN-2 (compound B6) is a highly selective inhibitor of Histone Deacetylase 11 (HDAC11). It demonstrates IC50 values of 51.1 ×10^-3 μM for HDAC11 and 5 μM for HDAC8. HDAC11-IN-2 reduces de novo lipogenesis (DNL) and enhances fatty acid oxidation, which alleviates hepatic lipid accumulation and pathological symptoms in MASLD mice. By inhibiting HDAC11, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at the Thr172 site, thereby modulating de novo lipogenesis and fatty acid oxidation in the liver.</p>Formule :C25H35N3O3Couleur et forme :SolidMasse moléculaire :425.564PRMT5-IN-48
CAS :<p>PRMT5-IN-48 (compound D3) is an orally active PRMT5 inhibitor with an IC50 of 20.7 nM, displaying antitumor activity. It effectively suppresses the growth of various cancer cells, induces apoptosis, and causes cell cycle arrest at the G0/G1 phase. PRMT5-IN-48 is applicable for research in non-Hodgkin's lymphoma (NHL).</p>Formule :C30H37N5O3Couleur et forme :SolidMasse moléculaire :515.646GSK3368715 3HCl
CAS :<p>GSK3368715, a potent inhibitor of type I protein arginine methyltransferases (PRMT), could inhibit PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81</p>Formule :C20H41Cl3N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :475.92DS79932728
CAS :<p>DS79932728 is an orally active inhibitor of G9a and GLP, with IC50 values of 12.6 nM and 75.7 nM, respectively. It induces the production of γ-globin, thereby increasing fetal hemoglobin (HbF) levels. In cynomolgus monkey models, DS79932728 enhances the proportion of F-reticulocytes (F-rets) and shows good oral absorption characteristics.</p>Formule :C19H25N3OCouleur et forme :SolidMasse moléculaire :311.421JAK3-IN-7
CAS :<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Formule :C17H20N6ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :324.38LNK01004
CAS :<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57HIF-2α-IN-5
CAS :<p>HIF-2α-IN-5 is a potent HIF-2α inhibitor with an IC 50 of < 50 nM [1].</p>Formule :C15H12F4O3S2Couleur et forme :SolidMasse moléculaire :380.38PRMT5-IN-37
CAS :<p>PRMT5-IN-37 (compound 29), an orally active inhibitor of PRMT5, is utilized for cancer research.</p>Formule :C21H15F4N5O2Couleur et forme :SolidMasse moléculaire :445.37JTZ-951 HCl
CAS :<p>JTZ-951 is a potent and orally active inhibitor of hypoxia inducible factor prolyl hydroxylase (PHD).</p>Formule :C17H17ClN4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :376.79lirucitinib
CAS :<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468FY-56
<p>FY-56: potent, selective LSD1/KDM1A inhibitor (IC50=42nM); differentiates MOLM-13/MV4-11 cells; promising for AML research.</p>Formule :C23H19FN2O3Couleur et forme :SolidMasse moléculaire :390.41DDO-3055
CAS :<p>DDO-3055 is an orally active PHD2 inhibitor utilized in studies related to anemia associated with chronic kidney disease.</p>Formule :C17H13ClN2O5Couleur et forme :SolidMasse moléculaire :360.749LSD1-IN-39
CAS :<p>LSD1-IN-39 (Compound 14) is a reversible inhibitor of LSD1 with an IC50 of 0.18 μM, showing broad-spectrum antiproliferative activity against cancer cells, inhibiting HepG2 cell migration, and suppressing epithelial-mesenchymal transition. Additionally, LSD1-IN-39 exhibits antitumor activity in mouse models.</p>Formule :C25H30N2O7Couleur et forme :SolidMasse moléculaire :470.515AMPK activator 16
CAS :<p>AMPK activator16 (compound 6) functions as an AMP-activated protein kinase (AMPK) inhibitor. It interacts effectively with crucial AMPK residues, significantly activating the enzyme. In N2a cells, AMPK activator16 enhances the expression of phosphorylated AMPK (p-AMPK) and its downstream signaling proteins, such as phosphorylated ACC (Acetyl-CoA Carboxylase) and phosphorylated raptor (p-raptor).</p>Formule :C23H20ClNO5SCouleur et forme :SolidMasse moléculaire :457.927CREB-IN-1 TFA
<p>CREB-IN-1 TFA: Potent oral CREB inhibitor, IC50 of 0.18 μM, suppresses breast cancer cell growth.</p>Couleur et forme :SolidSTR-V-53
CAS :<p>STR-V-53, an HDAC inhibitor (IC50 in nM), increases histone acetylation in tumor cells by inhibiting these enzymes, thereby regulating gene expression. STR-V-53 inhibits tumor growth and induces apoptosis [1].</p>Formule :C21H30N4O8Couleur et forme :SolidMasse moléculaire :466.48Purinostat
CAS :<p>Purinostat is a selective inhibitor of HDACI/IIb with potential anti-leukemic properties. Its mesylate form, Purinostat mesylate, is effective at inhibiting the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDACI/IIb, impacting several crucial factors for leukemia stem cell (LSC) survival, such as c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Additionally, Purinostat mesylate enhances glutamate metabolism in LSCs by increasing GLS1.</p>Formule :C23H26N10O3Couleur et forme :SolidMasse moléculaire :490.518LSD1-IN-15
<p>LSD1-IN-15 inhibits LSD1, MAO-A/B with IC50s: 0.149, 0.028, 0.327 μM; arrests LNCaP cancer cell growth, IC50 9.9 μM.</p>Formule :C22H20N2OCouleur et forme :SolidMasse moléculaire :328.41JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Couleur et forme :SolidGDC-0339
CAS :<p>GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.</p>Formule :C20H22F3N7OSCouleur et forme :SolidMasse moléculaire :465.5PARP-1/HDAC-IN-1
CAS :<p>PARP-1/HDAC-IN-1 is a PARP-1 and HDAC6 inhibitor with anticancer, antimigratory, and antiangiogenic activities and is used in tumor research.</p>Formule :C22H18N4O4Degré de pureté :95.94%Couleur et forme :SolidMasse moléculaire :402.4PRMT5-MTA-IN-3
CAS :<p>PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It inhibits the proliferation of MTAP-deficient colorectal cancer HCT-116 cell line with an IC50 value of 5 nM. PRMT5-MTA-IN-3 holds potential for research in cancers, particularly in MTAP-deficient tumors such as colorectal cancer, non-small cell lung cancer, and pancreatic cancer.</p>Formule :C19H17F3N6O3Couleur et forme :SolidMasse moléculaire :434.372Pociredir
CAS :<p>Pociredir (FTX-6058), a potent EED inhibitor (KD=0.163 nM), may help in SCD research.</p>Formule :C22H18FN5O2Couleur et forme :SolidMasse moléculaire :403.41LSD1-IN-22
<p>LSD1-IN-22: potent LSD1 inhibitor, K_i 98 nM, curbs cancer cell growth.</p>Formule :C9H8BrF2NCouleur et forme :SolidMasse moléculaire :248.07I-BET282E
<p>I-BET282E inhibits eight BET bromodomains (pIC50 6.4-7.7) with selectivity for other bromodomain proteins.</p>Formule :C26H34N4O7SCouleur et forme :SolidMasse moléculaire :546.64MS117
<p>MS117 is a first-in-class and cell-active irreversible covalent inhibitor of protein arginine methyltransferase 6 (PRMT6) (IC50 = 18 nM) [1].</p>Formule :C17H22N4OCouleur et forme :SolidMasse moléculaire :298.38
